TCR2 THERAPEUTICS INC.
TCR2 THERAPEUTICS INC. (TCRR): 4 pipeline candidates · ~9 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
8.7 months
D/E 0.50 · 0% dilution
Lead: Phase 1/Phase 2
4 candidates
N/A
N/A
A transparent, data-derived signal for TCR2 THERAPEUTICS INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$15.6M
Quarterly Burn
$40.0M
Runway
8.7 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| fludarabine | Phase 1/Phase 2 |
| gavo-cel | Phase 1/Phase 2 |
| tc-510 | Phase 1/Phase 2 |
| tc-520 | Phase 1/Phase 2 |
Frequently asked questions
How many drug candidates are in TCR2 THERAPEUTICS INC.'s pipeline?
TCR2 THERAPEUTICS INC. (TCRR) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is TCR2 THERAPEUTICS INC.'s lead drug candidate?
TCR2 THERAPEUTICS INC.'s most advanced tracked candidate is fludarabine (Phase 1/Phase 2) for Mesothelioma.
What is TCR2 THERAPEUTICS INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, TCR2 THERAPEUTICS INC. has approximately 8.7 months of cash runway.
Who is the CEO of TCR2 THERAPEUTICS INC.?
Massachusetts September is the chief executive officer of TCR2 THERAPEUTICS INC. (TCRR).
Get the full picture on TCR2 THERAPEUTICS INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.